Search

Search Constraints

You searched for: Author/Creator Burges, Alexander

Search Results

1. 2022-RA-798-ESGO Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II). (20th October 2022)

2. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). Issue 12 (30th June 2020)

3. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020)

4. Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905–1914]. (September 2016)

5. COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. (December 2021)

6. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Issue 9 (12th April 2019)

7. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. Issue 4 (1st February 2023)

8. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. Issue 5 (27th January 2023)

9. Perioperative management of positioning in gynecological cancersurgery: a national NOGGO-AGO intergroup survey. Issue 10 (16th August 2020)

10. Perioperative management of positioning in gynecological cancersurgery: a national NOGGO-AGO intergroup survey. Issue 10 (16th October 2020)